Artius II Acquisition Inc.
Historical Data
View all| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Jul 3, 2026 | $21.22 | $21.54 | $21.00 | $21.07 | 13.15M |
| Jul 2, 2026 | $20.80 | $21.43 | $20.22 | $21.22 | 21.29M |
| Jul 1, 2026 | $21.05 | $21.21 | $20.70 | $20.80 | 18.19M |
| Jun 30, 2026 | $20.45 | $22.02 | $19.91 | $21.05 | 17.56M |
| Jun 29, 2026 | $20.34 | $20.55 | $20.24 | $20.45 | 24.11M |
| Jun 28, 2026 | $20.09 | $20.61 | $19.76 | $20.34 | 26.25M |
| Jun 27, 2026 | $19.99 | $20.22 | $19.84 | $20.09 | 23.94M |
| Jun 26, 2026 | $19.50 | $20.38 | $19.03 | $19.99 | 24.10M |
Company Overview
Artius II Acquisition Inc. operates in the healthcare space within the Healthcare sector. The company generates the majority of its revenue from operating momentum, and has built a durable competitive position through scale, brand, and continued reinvestment. It serves customers globally and is headquartered in the United States. Reported figures on this page are generated for demonstration and are not investment advice.
Leadership
Board 13 · Independent 10 of 13| Date | Firm | Target | Rating |
|---|---|---|---|
| Jun 30 | Wedbush | — | Neutral |
| Jun 29 | Rosenblatt | $33.80 | Overweight |
| Jun 23 | Rosenblatt | $24.99 | Neutral |
| Jun 5 | Tigress Financial | $30.20 | Buy |
| May 24 | Morgan Stanley | $26.39 | Neutral |
| May 12 | Goldman Sachs | $26.92 | Overweight |
Politician Trades
View allWhat's Happening Right Now
- May 6, 2026 · Earnings ↗ — Artius II Acquisition reported 1Q 2026 net income of $245,387 (EPS $0.01) in its 10-Q filing.
- Aug 20, 2026 · Trading ↗ — AACB shares moved 0.09% higher to $10.59, trading within a supplied band of $10.06 to $11.12.
- Aug 10, 2026 · Trading ↗ — AACB held near $10.57 as the SPAC consolidated in a tight trading range.
- May 10, 2025 · Filing ↗ — Artius II Acquisition filed its 10-K form and other latest SEC filings for 2026.
Snapshot
Artius II Acquisition Inc. is a pre-revenue SPAC with $0.00 in FY2025 revenue, consistent with its blank-check company structure that has not yet completed a business combination. The company posted a $7.94M operating loss for the year but ended with net income of $136.24K, likely aided by trust-account interest income. Operating cash flow was positive at $842.15K, while capital expenditures of $1.68M pushed free cash flow to -$842.15K. Cash and equivalents stood at a thin $32.19K against zero total debt, underscoring reliance on trust funds rather than operating cash for liquidity.
Bottom Line
AACB remains a cash-shell SPAC with no operating revenue, a wide operating loss, and minimal free cash on hand outside its trust account, meaning its value proposition rests entirely on the prospects of a future merger target rather than current operations. The lack of debt limits downside financial risk, but investors are essentially betting on deal execution and target quality, not fundamentals. Recent share-price action shows the stock consolidating in a narrow band, suggesting the market is awaiting a definitive combination announcement.